Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SP-420
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PK data confirmed that the doses of SP-420 planned for the company's upcoming Phase 1-2 trial in patients with transfusional iron overload (TIO) should provide sufficient drug exposure for the desired therapeutic effect.
Product Name : SP-420
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : SP-420
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
